JP2021046398A5 - - Google Patents

Download PDF

Info

Publication number
JP2021046398A5
JP2021046398A5 JP2020182295A JP2020182295A JP2021046398A5 JP 2021046398 A5 JP2021046398 A5 JP 2021046398A5 JP 2020182295 A JP2020182295 A JP 2020182295A JP 2020182295 A JP2020182295 A JP 2020182295A JP 2021046398 A5 JP2021046398 A5 JP 2021046398A5
Authority
JP
Japan
Prior art keywords
treatment
composition
use according
patients
amh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020182295A
Other languages
English (en)
Japanese (ja)
Other versions
JP7373479B2 (ja
JP2021046398A (ja
Filing date
Publication date
Priority claimed from JP2020512546A external-priority patent/JP6856819B2/ja
Application filed filed Critical
Publication of JP2021046398A publication Critical patent/JP2021046398A/ja
Publication of JP2021046398A5 publication Critical patent/JP2021046398A5/ja
Application granted granted Critical
Publication of JP7373479B2 publication Critical patent/JP7373479B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020182295A 2017-09-01 2020-10-30 調節卵巣刺激のための組成物 Active JP7373479B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01
EP17189119.5 2017-09-01
JP2020512546A JP6856819B2 (ja) 2017-09-01 2018-08-31 調節卵巣刺激のための組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020512546A Division JP6856819B2 (ja) 2017-09-01 2018-08-31 調節卵巣刺激のための組成物

Publications (3)

Publication Number Publication Date
JP2021046398A JP2021046398A (ja) 2021-03-25
JP2021046398A5 true JP2021046398A5 (cg-RX-API-DMAC7.html) 2021-10-07
JP7373479B2 JP7373479B2 (ja) 2023-11-02

Family

ID=59772482

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020512546A Active JP6856819B2 (ja) 2017-09-01 2018-08-31 調節卵巣刺激のための組成物
JP2020182295A Active JP7373479B2 (ja) 2017-09-01 2020-10-30 調節卵巣刺激のための組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020512546A Active JP6856819B2 (ja) 2017-09-01 2018-08-31 調節卵巣刺激のための組成物

Country Status (32)

Country Link
US (2) US11744879B2 (cg-RX-API-DMAC7.html)
EP (3) EP3973982B1 (cg-RX-API-DMAC7.html)
JP (2) JP6856819B2 (cg-RX-API-DMAC7.html)
KR (2) KR20200045543A (cg-RX-API-DMAC7.html)
CN (2) CN111050787A (cg-RX-API-DMAC7.html)
AR (1) AR112541A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018326556B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020003379A2 (cg-RX-API-DMAC7.html)
CA (1) CA3073624A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020000482A1 (cg-RX-API-DMAC7.html)
DK (2) DK3973982T3 (cg-RX-API-DMAC7.html)
EA (1) EA202090480A1 (cg-RX-API-DMAC7.html)
ES (2) ES2904787T3 (cg-RX-API-DMAC7.html)
FI (1) FI3973982T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20241171T1 (cg-RX-API-DMAC7.html)
HU (2) HUE056726T2 (cg-RX-API-DMAC7.html)
IL (1) IL272763B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20200034B1 (cg-RX-API-DMAC7.html)
LT (2) LT3973982T (cg-RX-API-DMAC7.html)
MA (2) MA50034B1 (cg-RX-API-DMAC7.html)
MD (2) MD3675894T2 (cg-RX-API-DMAC7.html)
MX (2) MX2020002235A (cg-RX-API-DMAC7.html)
MY (1) MY200791A (cg-RX-API-DMAC7.html)
PH (1) PH12020500404A1 (cg-RX-API-DMAC7.html)
PL (2) PL3973982T3 (cg-RX-API-DMAC7.html)
PT (2) PT3973982T (cg-RX-API-DMAC7.html)
RS (2) RS65945B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202003840QA (cg-RX-API-DMAC7.html)
SI (2) SI3973982T1 (cg-RX-API-DMAC7.html)
TW (1) TWI749255B (cg-RX-API-DMAC7.html)
UA (1) UA126869C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019043143A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3973982T1 (sl) 2017-09-01 2024-10-30 Ferring B. V. Sestavek za nadzorovano stimulacijo jajčnikov
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1250148B2 (en) * 2000-01-27 2008-07-02 Laboratoires Serono SA Use of fsh for treating infertility
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
ES2494928T3 (es) * 2007-09-21 2014-09-16 Pharmabrand S.A. Composición que comprende polisacáridos mucilaginosos derivados de Aloe barbadensis combinados con liposomas, procedimiento para la obtención de los mismos y su uso como protector solar, un agente antiacné, un regenerador epidérmico y un hidratante
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
WO2011089602A2 (en) * 2010-01-21 2011-07-28 Ramot At Tel-Aviv University Ltd. Aloe-emodin derivatives and use thereof for the treatment of cancer
US9320778B2 (en) 2010-09-29 2016-04-26 Ferring B.V. Method for controlled ovarian stimulation with combined FSH and hCG
WO2012168680A1 (en) 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AR100132A1 (es) 2014-04-18 2016-09-14 Glycotope Gmbh Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino
EP3261661B1 (en) 2015-02-26 2023-10-18 Ferring B.V. Menotropin for treating infertility
HUE054300T2 (hu) 2015-04-17 2021-08-30 Ferring Bv FSH-t tartalmazó, meddõség kezelésére szolgáló készítmény
RS61163B1 (sr) 2015-04-24 2021-01-29 Ferring Bv Postupak proizvodnje gonadotrofina
US10906953B2 (en) 2015-06-26 2021-02-02 Ferring B.V. Methods of purification and/or viral inactivation
SI3973982T1 (sl) 2017-09-01 2024-10-30 Ferring B. V. Sestavek za nadzorovano stimulacijo jajčnikov
WO2019211153A1 (en) 2018-04-30 2019-11-07 Ferring B.V. Composition for controlled ovarian stimulation
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Similar Documents

Publication Publication Date Title
JP2022031772A5 (cg-RX-API-DMAC7.html)
JP2024530310A (ja) T細胞リンパ腫治療薬の調製におけるezh2阻害剤の使用
JP2018513188A5 (cg-RX-API-DMAC7.html)
JP2019511488A5 (cg-RX-API-DMAC7.html)
JP2016516016A5 (cg-RX-API-DMAC7.html)
IL307966A (en) Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
JP2008520544A5 (ja) 癌関連疲労の治療または予防のための医薬の製造への使用方法
CN106581641B (zh) 一种多肽在预防或治疗心肌缺血再灌注损伤相关疾病中的药物应用
Prevention Committee of the Japanese Society for Tuberculosis et al. Treatment guidelines for latent tuberculosis infection
JP2018519366A5 (cg-RX-API-DMAC7.html)
JP2020500864A5 (cg-RX-API-DMAC7.html)
JP2014508758A5 (cg-RX-API-DMAC7.html)
JP2017519799A5 (cg-RX-API-DMAC7.html)
JP2020536121A5 (cg-RX-API-DMAC7.html)
Godoy et al. Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome?
JP2025072354A (ja) チルゼパチド治療方法
JP2020526525A5 (cg-RX-API-DMAC7.html)
Yang et al. Percutaneous A1 pulley release combined with finger splint for trigger finger with proximal interphalangeal joint flexion contracture
JP2024512255A5 (cg-RX-API-DMAC7.html)
WO2021199006A1 (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
JP2021004249A5 (cg-RX-API-DMAC7.html)
JP2025508043A (ja) 血友病aの治療方法
FI3973982T3 (fi) Koostumus munasarjojen kontrolloituun stimulaatioon
JP2007501806A5 (cg-RX-API-DMAC7.html)
Absher Aggravation of myasthenia gravis by erythromycin